EP3472316A4 - Anti-c5-antikörper und verfahren zur verwendung - Google Patents

Anti-c5-antikörper und verfahren zur verwendung Download PDF

Info

Publication number
EP3472316A4
EP3472316A4 EP17813418.5A EP17813418A EP3472316A4 EP 3472316 A4 EP3472316 A4 EP 3472316A4 EP 17813418 A EP17813418 A EP 17813418A EP 3472316 A4 EP3472316 A4 EP 3472316A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17813418.5A
Other languages
English (en)
French (fr)
Other versions
EP3472316A1 (de
Inventor
Yoshinao Ruike
Zenjiro Sampei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP3472316A1 publication Critical patent/EP3472316A1/de
Publication of EP3472316A4 publication Critical patent/EP3472316A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP17813418.5A 2016-06-17 2017-06-16 Anti-c5-antikörper und verfahren zur verwendung Pending EP3472316A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016120325 2016-06-17
PCT/JP2017/022253 WO2017217524A1 (en) 2016-06-17 2017-06-16 Anti-c5 antibodies and methods of use

Publications (2)

Publication Number Publication Date
EP3472316A1 EP3472316A1 (de) 2019-04-24
EP3472316A4 true EP3472316A4 (de) 2020-01-08

Family

ID=59969459

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17813418.5A Pending EP3472316A4 (de) 2016-06-17 2017-06-16 Anti-c5-antikörper und verfahren zur verwendung

Country Status (19)

Country Link
EP (1) EP3472316A4 (de)
JP (3) JP6202774B1 (de)
KR (2) KR101852739B1 (de)
CN (3) CN115925922A (de)
AU (1) AU2017285763B2 (de)
BR (1) BR112018075688A2 (de)
CA (1) CA3021956A1 (de)
CL (1) CL2018003573A1 (de)
CR (1) CR20190013A (de)
EA (1) EA201990018A1 (de)
IL (2) IL300611A (de)
MX (2) MX2018015030A (de)
MY (1) MY187848A (de)
PE (2) PE20240825A1 (de)
PH (1) PH12018502354A1 (de)
SG (2) SG11201705584VA (de)
TW (4) TWI610941B (de)
UA (1) UA126561C2 (de)
WO (1) WO2017217524A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
DK2275443T3 (en) 2008-04-11 2016-02-08 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repetitively binding to two or more antigen molecules
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
JP7102353B2 (ja) 2016-06-14 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃ５抗体及びそれらの使用
UA126561C2 (uk) * 2016-06-17 2022-11-02 Чугаі Сейяку Кабусікі Кайся Застосування антитіла проти с5
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd A preparation for the prevention or treatment of diseases related to il-8
MX2020003619A (es) * 2017-10-04 2020-10-28 Alexion Pharma Inc Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa.
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
BR112021004141A2 (pt) * 2018-09-06 2021-05-25 The Trustees Of The University Of Pennsylvania anticorpo dependente de ph que se liga especificamente a c5 humano, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, célula, e, animal não humano geneticamente modificado.
SG11202111419QA (en) * 2019-04-24 2021-11-29 Univ Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
JP7494413B2 (ja) 2020-07-15 2024-06-04 ビオシオン インコーポレイテッド Ｃ５に結合する抗体及びその用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016098356A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0230985Y2 (de) 1985-07-08 1990-08-21
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
KR100716392B1 (ko) 2001-06-12 2007-05-11 텔레폰악티에볼라겟엘엠에릭슨(펍) Ｕｍｔｓ 지상 무선 액세스 네트워크(ｕｔｒａｎ)에서의동기화 방법 및 시스템
MX342385B (es) 2001-08-17 2016-09-27 Genentech Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b.
JP4333939B2 (ja) 2001-08-27 2009-09-16 ロード・コーポレーション トロリ線の吊架装置
DE10253331A1 (de) 2002-11-14 2004-06-03 Symrise Gmbh & Co. Kg Verwendung von trans-Pellitori als Aromastoff
US7267849B2 (en) 2004-03-02 2007-09-11 Nitto Denko Corporation Compensator for liquid crystal display
KR20080069889A (ko) 2007-03-20 2008-07-29 (주)화도 폴리에틸렌 관
WO2008113834A2 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
JP5336846B2 (ja) 2007-04-11 2013-11-06 積水化学工業株式会社 架橋ポリビニルアセタール樹脂の製造方法及び架橋ポリビニルアセタール樹脂
DK2275443T3 (en) * 2008-04-11 2016-02-08 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repetitively binding to two or more antigen molecules
CN102170906B (zh) * 2008-08-05 2014-07-30 诺华股份有限公司 靶定补体蛋白c5的抗体的组合物和方法
KR20100054403A (ko) 2008-11-14 2010-05-25 삼성전자주식회사 온라인 공동 작문 장치 및 방법
JP5932670B2 (ja) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
KR20110111007A (ko) 2010-04-02 2011-10-10 이화여자대학교 산학협력단 Ｌ／ｄ 광학변환 및 광학분할을 위한 옥타하이드로-바이나프톨 유도체
KR20110122011A (ko) 2010-05-03 2011-11-09 황보철종 매장 포인트 통합 관리 시스템 및 그 방법
NZ704771A (en) * 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
BR112015018438A2 (pt) * 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
US20160051673A1 (en) * 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
JP6088703B1 (ja) * 2015-12-18 2017-03-01 中外製薬株式会社 抗ｃ５抗体および使用方法
UA126561C2 (uk) * 2016-06-17 2022-11-02 Чугаі Сейяку Кабусікі Кайся Застосування антитіла проти с5

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016098356A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKU FUKUZAWA ET AL: "Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases", SCIENTIFIC REPORTS, vol. 7, no. 1, 24 April 2017 (2017-04-24), XP055399003, DOI: 10.1038/s41598-017-01087-7 *

Also Published As

Publication number Publication date
SG11201705584VA (en) 2018-05-30
CN115925922A (zh) 2023-04-07
KR101852739B1 (ko) 2018-04-30
TW201808996A (zh) 2018-03-16
PE20190394A1 (es) 2019-03-13
CL2018003573A1 (es) 2019-02-01
CA3021956A1 (en) 2017-12-21
TWI789369B (zh) 2023-01-11
TWI610941B (zh) 2018-01-11
MY187848A (en) 2021-10-26
MX2023001360A (es) 2023-02-27
JP7032077B2 (ja) 2022-03-08
EP3472316A1 (de) 2019-04-24
PH12018502354A1 (en) 2019-09-23
CN109312326A (zh) 2019-02-05
PE20240825A1 (es) 2024-04-18
WO2017217524A1 (en) 2017-12-21
AU2017285763A1 (en) 2018-11-08
MX2018015030A (es) 2019-04-22
RU2019100222A3 (de) 2020-11-05
AU2017285763B2 (en) 2024-02-01
KR20190009273A (ko) 2019-01-28
IL300611A (en) 2023-04-01
UA126561C2 (uk) 2022-11-02
SG10201800265UA (en) 2018-02-27
JP2018009021A (ja) 2018-01-18
CN115960223A (zh) 2023-04-14
JP2022091748A (ja) 2022-06-21
TW201809000A (zh) 2018-03-16
TW202337903A (zh) 2023-10-01
JP2017226655A (ja) 2017-12-28
JP6202774B1 (ja) 2017-09-27
KR102226975B1 (ko) 2021-03-11
BR112018075688A2 (pt) 2019-04-02
TW202239766A (zh) 2022-10-16
CR20190013A (es) 2019-03-05
IL263657A (en) 2019-01-31
EA201990018A1 (ru) 2019-08-30
TWI807666B (zh) 2023-07-01
RU2019100222A (ru) 2020-07-17
CN109312326B (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
IL265800A (en) Anti-lag-3 antibodies and methods of using them
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
EP3233921A4 (de) Anti-c5-antikörper und verfahren zur verwendung
HUE062927T2 (hu) Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
EP3515478A4 (de) Antikörper für siglec-15 und verfahren zur verwendung davon
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
EP3383430A4 (de) Antikörper und verfahren zur verwendung davon
EP3454900A4 (de) Cd47-antikörper und verfahren zur verwendung davon
EP3472316A4 (de) Anti-c5-antikörper und verfahren zur verwendung
HUE062436T2 (hu) Anti-trem2 antitestek és alkalmazási módszereik
EP3383914A4 (de) Anti-ox40-antikörper und verfahren zur verwendung davon
EP3280441A4 (de) Anti-sortilin-antikörper und verfahren zur verwendung davon
EP3390442A4 (de) Anti-c5-antikörper und verfahren zur verwendung
EP3177322A4 (de) Anti-trem2-antikörper und verfahren zur verwendung davon
EP3472200A4 (de) Anti-myostatin-antikörper und verfahren zur verwendung
EP3116911B8 (de) Anti-mcam-antikörper und zugehöriges verfahren zur verwendung
EP3383917A4 (de) Neuartige anti-claudin-antikörper und verfahren zur verwendung
EP3491025A4 (de) Fcrn-antikörper und verfahren zur verwendung davon
EP3134121A4 (de) Neuartige anti-rnf43-antikörper und verfahren zur verwendung
EP3280440A4 (de) Humanisierte anti-c1s-antikörper und verfahren zur verwendung davon
EP3728323A4 (de) Anti-frizzled-antikörper und verfahren zur verwendung
EP3559042A4 (de) Anti-lilrb3-antikörper und verfahren zur verwendung davon
EP3189079A4 (de) Neuartige anti-mfi2-antikörper und verfahren zur verwendung
IL265957A (en) Anti-c1s antibodies and methods of using them
EP3684819A4 (de) Anti-ykl40-antikörper und verfahren zur verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191210

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101AFI20191204BHEP

Ipc: A61P 7/00 20060101ALI20191204BHEP

Ipc: C12N 15/09 20060101ALI20191204BHEP

Ipc: A61K 39/395 20060101ALI20191204BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220923